155 related articles for article (PubMed ID: 32587277)
21. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
[TBL] [Abstract][Full Text] [Related]
22. New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells.
Amanzadeh A; Molla-Kazemiha V; Samani S; Habibi-Anbouhi M; Azadmanesh K; Abolhassani M; Shokrgozar MA
Leuk Res; 2018 May; 68():98-104. PubMed ID: 29602066
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.
Albanesi J; Noguera NI; Banella C; Colangelo T; De Marinis E; Leone S; Palumbo O; Voso MT; Ascenzi P; Nervi C; Bianchi F; di Masi A
Cells; 2020 Nov; 9(11):. PubMed ID: 33167477
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
25. Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia.
Csomós K; Német I; Fésüs L; Balajthy Z
Blood; 2010 Nov; 116(19):3933-43. PubMed ID: 20739659
[TBL] [Abstract][Full Text] [Related]
26. HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.
Tang L; Chai W; Ye F; Yu Y; Cao L; Yang M; Xie M; Yang L
Oncotarget; 2017 Apr; 8(16):27314-27327. PubMed ID: 28404891
[TBL] [Abstract][Full Text] [Related]
27. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
Niitsu N; Ishii Y; Matsuda A; Honma Y
Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
[TBL] [Abstract][Full Text] [Related]
28. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil secondary-granule deficiency as a hallmark of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.
Miyauchi J; Ohyashiki K; Inatomi Y; Toyama K
Blood; 1997 Jul; 90(2):803-13. PubMed ID: 9226181
[TBL] [Abstract][Full Text] [Related]
31. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
34. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Jing Y; Wang L; Xia L; Chen GQ; Chen Z; Miller WH; Waxman S
Blood; 2001 Jan; 97(1):264-9. PubMed ID: 11133770
[TBL] [Abstract][Full Text] [Related]
35. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
36. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
37. Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.
Orfali N; O'Donovan TR; Nyhan MJ; Britschgi A; Tschan MP; Cahill MR; Mongan NP; Gudas LJ; McKenna SL
Exp Hematol; 2015 Sep; 43(9):781-93.e2. PubMed ID: 25986473
[TBL] [Abstract][Full Text] [Related]
38. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Gausdal G; Wergeland A; Skavland J; Nguyen E; Pendino F; Rouhee N; McCormack E; Herfindal L; Kleppe R; Havemann U; Schwede F; Bruserud O; Gjertsen BT; Lanotte M; Ségal-Bendirdjian E; Døskeland SO
Cell Death Dis; 2013 Feb; 4(2):e516. PubMed ID: 23449452
[TBL] [Abstract][Full Text] [Related]
39. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
40. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
